drug-induced parkinsonism

drug-induced parkinsonism
Name	Drug-induced parkinsonism
Field	Neurology, Clinical pharmacology
Causes	Dopamine receptor blockade
Risks	Antipsychotic use, Metoclopramide therapy
Diagnosis	Clinical history, Neurological examination
Differential	Parkinson's disease, Vascular parkinsonism
Prevention	Judicious prescribing
Treatment	Discontinuation of offending agent
Medication	Anticholinergic agents
Prognosis	Often reversible

drug-induced parkinsonism is a common and often reversible syndrome of Parkinsonism caused by the administration of certain medications. It clinically mimics Parkinson's disease, presenting with Bradykinesia, rigidity, and Tremor. The condition is most frequently associated with drugs that antagonize Dopamine receptors in the Basal ganglia, particularly Typical antipsychotics and antiemetics like Metoclopramide. Accurate diagnosis is crucial to differentiate it from neurodegenerative forms and to guide appropriate management, which primarily involves withdrawal of the causative agent.

Definition and Overview

This condition is formally defined as an acquired form of parkinsonism directly attributable to pharmacological agents, without evidence of underlying Lewy body pathology. It represents one of the most prevalent causes of secondary parkinsonism worldwide, often seen in patients treated for Psychosis or Gastrointestinal disease. The seminal work of clinicians like Arvid Carlsson, who elucidated the role of Dopamine in motor control, provided the foundational understanding for this iatrogenic disorder. Its recognition became prominent following the widespread clinical use of Chlorpromazine and other Neuroleptics in the mid-20th century, as documented in journals like The Lancet.

Causes and Pathophysiology

The primary cause is the pharmacological blockade of postsynaptic D2 receptors in the Nigrostriatal pathway. The most common offending drug classes include Typical antipsychotics such as Haloperidol and Fluphenazine, and the antiemetic Metoclopramide. Other implicated agents include some Calcium channel blockers like Cinnarizine, certain Antidepressants such as Fluoxetine, and the Antiepileptic drug Valproate. The pathophysiology involves a functional reduction in Dopaminergic neurotransmission within the Striatum, leading to a relative excess of Acetylcholine activity, mirroring the neurochemical imbalance seen in Parkinson's disease.

Clinical Presentation and Diagnosis

Patients typically present with the classic triad of Parkinsonism: Akinesia, muscular rigidity, and a Resting tremor. Symptoms are often symmetric, unlike the typically asymmetric onset of Parkinson's disease. Diagnosis relies heavily on a detailed Medication history identifying exposure to a causative drug. Neurological examination by a specialist in Movement disorders is essential. While DaTscan imaging can show preserved Dopamine transporter function, distinguishing it from Neurodegeneration, its use is guided by clinical uncertainty. The diagnostic criteria are often discussed in forums like the International Parkinson and Movement Disorder Society.

Differential Diagnosis

Key conditions to distinguish include Parkinson's disease, Multiple system atrophy, Progressive supranuclear palsy, and Vascular parkinsonism. Other secondary causes like Normal pressure hydrocephalus and Wilson's disease must also be considered. The symmetry of symptoms and temporal relationship to drug initiation are critical differentiating factors. Investigations may include Magnetic resonance imaging to rule out Cerebrovascular disease or structural lesions, and sometimes a therapeutic trial of Levodopa, to which drug-induced cases are typically less responsive.

Management and Treatment

The cornerstone of management is the discontinuation or dose reduction of the offending medication, under the supervision of the prescribing physician, such as a Psychiatrist or Gastroenterologist. If cessation is not possible, switching to an Atypical antipsychotic with lower Dopamine receptor affinity, like Quetiapine or Clozapine, may be considered. For persistent symptoms, Anticholinergic agents such as Trihexyphenidyl or Benztropine can provide symptomatic relief. In severe cases, consultation with a neurologist at an institution like the Mayo Clinic or National Institutes of Health may be warranted.

Prognosis and Prevention

The prognosis is generally favorable, with symptoms often resolving within weeks to months after withdrawal of the causative drug. However, in some patients, particularly the elderly, recovery may be incomplete, leading to the hypothesis that the drug may unmask a preclinical Neurodegenerative disease. Prevention centers on the judicious use of high-risk medications, especially in vulnerable populations. Educational initiatives by organizations like the World Health Organization and the Food and Drug Administration promote awareness among prescribers to minimize this iatrogenic complication.

Category:Neurological disorders Category:Adverse effects of drugs